Prophylaxis for thromboembolism in hospitalized medical patients [10]

New England Journal of Medicine

Volumn 357, Issue 3, 2007, Pages 305-

  Famularo, Giuseppe ^a   Minisola, Giovanni ^a   De Simone, Claudio ^b  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

BLEEDING; BODY SURFACE; BODY WEIGHT; DRUG CLEARANCE; DRUG COST; DRUG HALF LIFE; GLOMERULUS FILTRATION RATE; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITALIZATION; HUMAN; LETTER; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HOSPITALIZATION; HUMANS; POLYSACCHARIDES; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 34447528986     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Donat F, Duret JP, Santoni A, et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002;41:Suppl 2:1-9.
2. Hulot JS, Vantelon C, Urien S, et al. Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment. Ther Drug Monit 2004;26:305-10.
3. Reverter JC. Fondaparinux sodium. Drugs Today (Barc) 2002;38:185-94.
4. Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review. Semin Thromb Hemost 2006;32:803-9.